HighPoint Advisor Group LLC Makes New Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

HighPoint Advisor Group LLC bought a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,199 shares of the biopharmaceutical company’s stock, valued at approximately $217,000.

Several other large investors also recently modified their holdings of the stock. Signaturefd LLC raised its stake in Intra-Cellular Therapies by 85.7% in the 4th quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 239 shares during the period. Neo Ivy Capital Management purchased a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at approximately $45,000. Cape Investment Advisory Inc. bought a new position in Intra-Cellular Therapies in the 4th quarter worth approximately $78,000. Parallel Advisors LLC grew its stake in Intra-Cellular Therapies by 16.3% in the 4th quarter. Parallel Advisors LLC now owns 1,564 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 219 shares in the last quarter. Finally, CI Investments Inc. raised its holdings in Intra-Cellular Therapies by 1,191.6% during the 3rd quarter. CI Investments Inc. now owns 1,692 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 1,561 shares during the period. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Up 1.4 %

NASDAQ ITCI opened at $76.58 on Friday. The stock’s 50-day simple moving average is $69.53 and its two-hundred day simple moving average is $68.69. Intra-Cellular Therapies, Inc. has a twelve month low of $45.50 and a twelve month high of $84.89. The company has a market capitalization of $8.08 billion, a price-to-earnings ratio of -66.02 and a beta of 0.97.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. Intra-Cellular Therapies had a negative return on equity of 18.49% and a negative net margin of 21.57%. The company had revenue of $144.90 million during the quarter, compared to the consensus estimate of $141.41 million. During the same quarter in the previous year, the company posted ($0.46) EPS. Intra-Cellular Therapies’s quarterly revenue was up 52.0% compared to the same quarter last year. On average, equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $86.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, April 3rd. Needham & Company LLC upped their price target on Intra-Cellular Therapies from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Tuesday, June 18th. The Goldman Sachs Group increased their price target on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a “neutral” rating in a report on Wednesday, April 17th. TD Cowen upped their target price on shares of Intra-Cellular Therapies from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Finally, Mizuho raised their price target on shares of Intra-Cellular Therapies from $96.00 to $100.00 and gave the company a “buy” rating in a report on Friday. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $92.67.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.